CONTEXT:  ICER using RWE predominantly for economic reviews and seldom in effectiveness evaluations.  IMPACT:  medium READ TIME:  2 mins Quality Level Mean [1 – 10]:  7 1. “Real-world evidence is used frequently in the Institute for Clinical and Economic Review (ICER) scoping process but infrequently in ICER comparative clinical effectiveness (CCE) assessments, according to a recent study published in the Journal of Managed Care and Specialty Pharmacy (2020;26[12]:1590-1595.”  2. ““[Real-world evidence] is used to inform ICER’s scoping and comparative clinical effectiveness (CCE) assessments, but the extent to which it is used has not been quantified,” they continued.”  3. “This study aimed to systematically evaluate the use of real-world evidence in the scoping and CCE assessment sections of the ICER health technology assessment (HTA) reports on pharmaceuticals.”  4. “All ICER reports of pharmaceuticals published between January 2014 and June 2019 were reviewed for the average number of instances and proportion of real-world evidence use in the scoping documents.”  5. “[Real-world evidence] was used infrequently in ICER CCE assessments, while more often used to inform effectiveness, safety, and treatment patterns in relevant clinical guidelines,” concluded Dr Jiao and colleagues.”  Source URL: https://www.journalofclinicalpathways.com/news/icer-use-real-world-evidence-scoping-process-and-clinical-evidence-assessments